A reverse merger will see two Massachusetts, USA-based companies, Q32 Bio and Homology Medicines (Nasdaq: FIXX), joining forces to focus on the former’s autoimm 20 November 2023
A biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, au 7 November 2023
American critical care specialist Citius Pharma is to list its oncology subsidiary on the Nasdaq exchange, via merger with a special purpose acquisition company 25 October 2023